Table 5.
Multivariate analysis of Cox proportional hazards model of 5-year OS and PFS for the patients of the CCRT group (n = 147)
| Prognostic factors | OS | PFS | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95 % CI | p value | Hazard ratio | 95 % CI | p value | |
| LMR: high versus low | 0.251 | 0.161–0.412 | 0.013 | 0.218 | 0.014–0.582 | 0.021 |
| HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA | 0.132 | 0.023–0.314 | 0.001 | 0.206 | 0.064–0.516 | 0.017 |
| Age: ≤46 versus >46 | 0.323 | 0.101–0.616 | 0.072 | 1.113 | 0.756–3.561 | 0.403 |
| FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA | 0.174 | 0.074–0.338 | 0.024 | 0.127 | 0.017–0.528 | 0.023 |
| pathological type: SCC versus ADC versus ASC versus UDC | 0.305 | 0.056–0.428 | 0.001 | 0.275 | 0.126–0.490 | 0.031 |
| Lymph node status classification: positive lymph node versus negative lymph node | 1.364 | 0.789–3.238 | 0.063 | 2.531 | 1.476–4.821 | 0.059 |
| ALC: high versus low | 0.458 | 0.198–0.824 | 0.021 | 0.512 | 0.165–0.928 | 0.013 |
| AMC: high versus low | 0.703 | 0.149–1.614 | 0.219 | 0.982 | 0.301–2.124 | 0.533 |
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count